Researchers assessed outcomes with different chemo regimen doses in elderly or frail patients with gastroesophageal cancer, in this study presented ahead of the ASCO Annual Meeting.
Researchers are evaluating Iodine (131I) apamistamab plus HCT vs conventional care in older patients with active relapsed/refractory acute myeloid leukemia.
This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.
This email was sent by: MultiMedia Healthcare
535 Connecticut Avenue, Suite 300
Norwalk, CT, 06854, USA